Dean Investment Associates LLC Sells 8,122 Shares of Encompass Health Co. (NYSE:EHC)

Dean Investment Associates LLC trimmed its stake in Encompass Health Co. (NYSE:EHC) by 12.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,207 shares of the company’s stock after selling 8,122 shares during the quarter. Encompass Health makes up about 0.8% of Dean Investment Associates LLC’s portfolio, making the stock its 29th biggest holding. Dean Investment Associates LLC owned 0.06% of Encompass Health worth $5,625,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. QRG Capital Management Inc. grew its stake in shares of Encompass Health by 85.6% in the second quarter. QRG Capital Management Inc. now owns 14,365 shares of the company’s stock valued at $1,232,000 after buying an additional 6,627 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Encompass Health in the 2nd quarter valued at about $2,204,000. Los Angeles Capital Management LLC increased its stake in shares of Encompass Health by 532.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock worth $4,860,000 after purchasing an additional 42,338 shares during the last quarter. Pathstone Holdings LLC raised its holdings in shares of Encompass Health by 54.5% in the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock valued at $2,032,000 after purchasing an additional 7,412 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Encompass Health in the 2nd quarter valued at about $541,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Price Performance

Shares of Encompass Health stock opened at $102.50 on Friday. The company has a 50-day simple moving average of $98.85 and a two-hundred day simple moving average of $91.96. Encompass Health Co. has a twelve month low of $64.15 and a twelve month high of $104.55. The stock has a market capitalization of $10.33 billion, a price-to-earnings ratio of 24.76, a price-to-earnings-growth ratio of 1.35 and a beta of 0.86. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.09. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the previous year, the company posted $0.86 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Analysts forecast that Encompass Health Co. will post 4.29 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s payout ratio is currently 16.43%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on EHC shares. UBS Group boosted their price target on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Barclays increased their price target on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Royal Bank of Canada lifted their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Truist Financial reissued a “buy” rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Finally, KeyCorp lifted their target price on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a report on Tuesday, October 29th. Nine equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $107.11.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.